Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2


  1. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147–156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bell JJ, Bhandoola A . The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452: 764–767.

    Article  CAS  PubMed  Google Scholar 

  3. Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322–4328.

    Article  CAS  PubMed  Google Scholar 

  4. Martinelli G, Iacobucci I, Paolini S, Ottaviani E . Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin Adv Hematol Oncol 2008; 6: 303–310.

    PubMed  Google Scholar 

  5. Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V et al. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia 2009; 23: 631–634.

    Article  CAS  PubMed  Google Scholar 

  6. Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005; 106: 3532–3537.

    Article  CAS  PubMed  Google Scholar 

  7. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24: 507–516.

    Article  CAS  PubMed  Google Scholar 

  8. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111: 2589–2596.

    Article  CAS  PubMed  Google Scholar 

Download references


We thank the Association ‘Morgan di Gianvittorio’ for funding and Ageop for support.

Author information

Authors and Affiliations


Corresponding author

Correspondence to C Biagi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Biagi, C., Astolfi, A., Masetti, R. et al. Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. Leukemia 24, 1230–1233 (2010).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links